Mount Sinai Hospital

Tisch Cancer Institute

New York, NY

Sorting 22 by

Not currently accepting

Talisman

A Phase 2, Open-label, Randomized Study to Evaluate Prophylactic Interventions on Talquetamab-related Oral Toxicity
  • Bispecific Antibody
  • GPRC5D
  • Randomization
  • Phase 2

Accepting patients

QUINTESSENTIAL

Phase 2 Study of BMS-986393, a GPRC5D-directed CART-Cell Therapy, in Participants with Relapsed or Refractory Multiple Myeloma
  • CAR T Cell
  • GPRC5D
  • Phase 2
All clinical trials have eligibility criteria - or a list of reasons why you may be able or unable to participate in a trial. Answer a few questions to view your personalized results - all in under 60 seconds.
Help me find trials

Accepting patients

BMS-986453

A Phase 1, Open-Label, Dose-Finding Study of BMS-986453, Dual Targeting BCMAxGPRC5D Chimeric Antigen Receptor T Cells, in Participants With Relapsed and/or Refractory Multiple Myeloma
  • CAR T Cell
  • BCMA
  • GPRC5D
  • Phase 1

Accepting patients

CARTITUDE-6

A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma (CARTITUDE-6)
  • Autologous Stem Cell Transplant
  • CAR T Cell
  • BCMA
  • Phase 3

Accepting patients

GCO12F CAR-T

A Phase 1b/2 Study of GC012F (AZD0120), a Chimeric Antigen Receptor T-cell (CAR T) Therapy Targeting CD19 and B-cell Maturation Antigen (BCMA) in Subjects With Relapsed/Refractory Multiple Myeloma
  • CAR T Cell
  • BCMA
  • CD19
  • Phase 1/2

Accepting patients

Etentamig

A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma
  • Bispecific Antibody
  • BCMA
  • Phase 1
  • Has results

Accepting patients

Etentamig

A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-383 in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma
  • Bispecific Antibody
  • Gamma-Secretase Inhibitor
  • BCMA
  • Phase 1
  • Has results

Accepting patients

Selinexor

Selinexor, Carfilzomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
  • SINE
  • Phase 1

Accepting patients

Investigational Cord Blood Units

Safety Study of Unlicensed, Investigational Cord Blood Units Manufactured by the National Cord Blood Program (NCBP) for Unrelated Transplantation
  • Allogeneic Stem Cell Transplant
  • Cord Blood
  • Phase 2

Accepting patients

Cemsidomide (CFT7455)

Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma
  • IKZF1/3
  • Phase 1/2
  • Has results
4 hidden based on your filters. Show All